John W. Mellors
University of Pittsburgh
443 Papers
5.5K Citations
John W. Mellors is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Medicine & Viral load. The author has an hindex of 78, co-authored 373 publications. Previous affiliations of John W. Mellors include East China University of Science and Technology & Case Western Reserve University.
Chat about Author
Papers
Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel
Martin S. Hirsch,Françoise Brun-Vézinet,Richard T. D'Aquila,Scott M. Hammer,Victoria A. Johnson,Daniel R. Kuritzkes,Clive Loveday,John W. Mellors,Bonaventura Clotet,Brian Conway,Lisa M. Demeter,Stefano Vella,Donna M. Jacobsen,Douglas D. Richman +13 more
TL;DR: The International AIDS Society-USA 13-member physician panel with expertise in basic science, clinical research, and patient care involving HIV resistance to antiretroviral drugs was reconvened to provide recommendations for the clinical use of drug resistance testing as discussed by the authors.
The COVID misinfodemic: not new, never more lethal
TL;DR: The authors compared and contrasted key elements of the AIDS and COVID-19 misinfodemics, to identify common features, and, based on experience with the AIDS pandemic, recommend actions to control and reverse the SARS-CoV-2 mis-infodemic that contributed to erode the trust between the public and scientists and governments and has created barriers to control of COVID19.
HIV-Infected African Americans are willing to participate in HIV Treatment trials
Mandy Garber,Barbara H. Hanusa,Galen E. Switzer,Galen E. Switzer,John W. Mellors,Robert M. Arnold +5 more
TL;DR: A questionnaire to develop a questionnaire that measures attitudes and concerns about HIV treatment trials among HIV-infected African Americans at a university-based clinic found neither trust/distrust in the medical profession nor beliefs about the dishonesty of researchers was associated with research participation rates or willingness to participate in future HIV treatment Trials.
Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy
Mary F. Kearney,Jonathan Spindler,Wei Shao,Sloane Yu,Elizabeth M. Anderson,Angeline O'Shea,Catherine Rehm,Carry Poethke,Nicholas Kovacs,John W. Mellors,John M. Coffin,Frank Maldarelli +11 more
TL;DR: The appearance of genetically uniform virus populations and the lack of divergence after prolonged cART and cART interruption provide strong evidence that HIV-1 persists in long-lived cells infected before cART was initiated, that some of these infected cells may be capable of proliferation, and that on-going cycles of viral replication are not evident.
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Anthony R. Cillo,Benedict B. Hilldorfer,Christina M. Lalama,John E. McKinnon,Robert W. Coombs,Allan R. Tenorio,Lawrence Fox,Rajesh T. Gandhi,Heather J. Ribaudo,Judith S. Currier,Roy M. Gulick,Timothy J. Wilkin,John W. Mellors +12 more
TL;DR: In individuals on suppressive ART with incomplete CD4+ T-cell recovery, maraviroc intensification did not affect measures of HIV-1 persistence but did decrease persistent CD4-T-cell immune activation especially in individuals with low preintensification levels of HIV -1 DNA.